Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN) KRAS G12C inhibitor abstract showed promising data at a huge cancer conference.
Amgen showcased its oncology pipeline at the 55th Annual Meeting of the American Society of Clinical Oncology, or ASCO, on Wednesday.
The first clinical data on Amgen’s KRAS G12C inhibitor was highly anticipated despite the project only being in phase one, according to the biotech news site Vantage.
Why It's Important
Mirati is also developing a KRAS G12C inhibitor, MRTX849, that is in studies for an investigational new drug application. Once an IND is filed and approved by the FDA, clinical trials may commence.
Mirati may experience volatility related to Amgen's fortunes with the pipeline candidate AMG 510, which in early stage development for certain types of cancer.
Mirati shares were trading up by 13.81 percent at $72.27 at the time of publication Thursday.
The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
See more from Benzinga
- Russian Payments Company Qiwi Trades Higher On Q1 Beat-And-Raise
- ESSA Pharma, Realm Therapeutics To Merge In M Deal
- Walmart Trades Higher On Q1 Earnings Beat
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.